SCHEMBL4412893

SCHEMBL4412893

O=C(O)N1CCC(OCc2noc(-c3ccc(C(=O)N4CCCC4)cc3)n2)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 4/20 0.47
SPHK2 Q9NRA0 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KCNH2 Q12809 1/20 0.44
MCHR1 Q99705 1/20 0.44
TSHR P16473 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
HDAC4 P56524 2/20 0.42
HDAC6 Q9UBN7 1/20 0.42
PTGS2 P35354 1/20 0.42
HPGD P15428 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
MGLL Q99685 1/20 0.41
MAPK1 P28482 1/20 0.41
CHRM2 P08172 1/20 0.40
NR1H4 Q96RI1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4422335 0.92 PTGS2 (0.51) SPHK1SPHK2SMN1; SMN2KCNH2MCHR1
SCHEMBL14640893 0.88 SPHK1 (0.49) SPHK1SPHK2SMN1; SMN2KCNH2MCHR1
SCHEMBL13598291 0.87 GPR119 (0.55) SPHK1SPHK2SMN1; SMN2HDAC4KMT2A
SCHEMBL4412979 0.85 SPHK1 (0.42) SPHK1SPHK2SMN1; SMN2KCNH2MCHR1
SCHEMBL4416567 0.85 SPHK1 (0.42) SPHK1SPHK2SMN1; SMN2KCNH2MCHR1
SCHEMBL4415854 0.83 SPHK2 (0.55) SPHK1SPHK2MCHR1HDAC4HDAC6
SCHEMBL4412654 0.81 GPR119 (0.40) SPHK1SPHK2KCNH2MCHR1HDAC4
SCHEMBL4424695 0.81 SPHK2 (0.49) SPHK1SPHK2MCHR1HDAC6
SCHEMBL4424803 0.81 SPHK1 (0.46) SPHK1SPHK2SMN1; SMN2MCHR1NPC1
SCHEMBL4415741 0.81 HDAC4 (0.43) SPHK1SPHK2KCNH2HDAC4HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325924-A1 GPCR Agonists GPR119, GCGR, GPR27 SPHK1 686/4885SPHK2 754/4885SMN1; SMN2 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.